重症筋無力症治療の世界市場 2020年

• 英文タイトル：Global Myasthenia Gravis Therapies Market 2020 by Company, Regions, Type and Application, Forecast to 2025

• レポートコード：GIR201114614 • 出版社/出版日：GlobalInfoResearch / 2020年10月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、105ページ • 納品方法：Eメール • 産業分類：医療

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本書では、重症筋無力症治療の世界市場を調査対象にし、重症筋無力症治療の市場概要、企業情報、企業別売上・市場シェア、地域別市場分析（北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ）、種類別分析（眼性重症筋無力症、先天性重症筋無力症、全身性重症筋無力症、一過性重症筋無力症、その他）、用途別分析（病院・診療所、診断センター、学術・研究機関）、市場予測（2021年～2025年）情報などを整理しました。 ・市場概要 ・企業情報：Alexion Pharmaceuticals、Grifols、Novartis、CSL Behring ・企業別売上、市場シェア ・重症筋無力症治療の地域別市場分析 ・重症筋無力症治療の北米市場規模2015-2020：アメリカ、カナダ、メキシコ ・重症筋無力症治療のヨーロッパ市場規模2015-2020：ドイツ、イギリス、フランス、ロシアなど ・重症筋無力症治療のアジア市場規模2015-2020：日本、中国、韓国、インド、東南アジアなど ・重症筋無力症治療の南米市場規模2015-2020：ブラジル、アルゼンチンなど ・重症筋無力症治療の中東・アフリカ市場規模2015-2020：サウジアラビア、トルコ、エジプト、南アフリカなど ・重症筋無力症治療の種類別市場規模2015-2020：眼性重症筋無力症、先天性重症筋無力症、全身性重症筋無力症、一過性重症筋無力症、その他 ・重症筋無力症治療の用途別市場規模2015-2020：病院・診療所、診断センター、学術・研究機関 ・重症筋無力症治療の世界市場予測2021-2025：地域別、種類別、用途別 ・調査の結果・結論

Market Overview
The global Myasthenia Gravis Therapies market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Myasthenia Gravis Therapies market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Myasthenia Gravis Therapies market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Myasthenia Gravis Therapies market has been segmented into:
Ocular Myasthenia Gravis
Congenital Myasthenia Gravis
Generalized Myasthenia Gravis
Transient Myasthenia Gravis
Others

By Application, Myasthenia Gravis Therapies has been segmented into:
Hospitals and Clinics
Diagnostic Centers
Academic and Research Organizations

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Myasthenia Gravis Therapies market presented in the report. This section sheds light on the sales growth of different regional and country-level Myasthenia Gravis Therapies markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Myasthenia Gravis Therapies market.

The report offers in-depth assessment of the growth and other aspects of the Myasthenia Gravis Therapies market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Myasthenia Gravis Therapies Market Share Analysis
Myasthenia Gravis Therapies competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Myasthenia Gravis Therapies sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Myasthenia Gravis Therapies sales, revenue and market share for each player covered in this report.

The major players covered in Myasthenia Gravis Therapies are:
Alexion Pharmaceuticals
Grifols
Novartis
CSL Behring

レポート目次

---

1 Myasthenia Gravis Therapies Market Overview
1.1 Product Overview and Scope of Myasthenia Gravis Therapies
1.2 Classification of Myasthenia Gravis Therapies by Type
1.2.1 Global Myasthenia Gravis Therapies Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Myasthenia Gravis Therapies Revenue Market Share by Type in 2019
1.2.3 Ocular Myasthenia Gravis
1.2.4 Congenital Myasthenia Gravis
1.2.5 Generalized Myasthenia Gravis
1.2.6 Transient Myasthenia Gravis
1.2.7 Others
1.3 Global Myasthenia Gravis Therapies Market by Application
1.3.1 Overview: Global Myasthenia Gravis Therapies Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals and Clinics
1.3.3 Diagnostic Centers
1.3.4 Academic and Research Organizations
1.4 Global Myasthenia Gravis Therapies Market by Regions
1.4.1 Global Myasthenia Gravis Therapies Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Myasthenia Gravis Therapies (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Myasthenia Gravis Therapies Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Myasthenia Gravis Therapies Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Myasthenia Gravis Therapies Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Myasthenia Gravis Therapies Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Myasthenia Gravis Therapies Status and Prospect (2015-2025)
2 Company Profiles
2.1 Alexion Pharmaceuticals
2.1.1 Alexion Pharmaceuticals Details
2.1.2 Alexion Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Alexion Pharmaceuticals SWOT Analysis
2.1.4 Alexion Pharmaceuticals Product and Services
2.1.5 Alexion Pharmaceuticals Myasthenia Gravis Therapies Revenue, Gross Margin and Market Share (2018-2019)
2.2 Grifols
2.2.1 Grifols Details
2.2.2 Grifols Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Grifols SWOT Analysis
2.2.4 Grifols Product and Services
2.2.5 Grifols Myasthenia Gravis Therapies Revenue, Gross Margin and Market Share (2018-2019)
2.3 Novartis
2.3.1 Novartis Details
2.3.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Novartis SWOT Analysis
2.3.4 Novartis Product and Services
2.3.5 Novartis Myasthenia Gravis Therapies Revenue, Gross Margin and Market Share (2018-2019)
2.4 CSL Behring
2.4.1 CSL Behring Details
2.4.2 CSL Behring Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 CSL Behring SWOT Analysis
2.4.4 CSL Behring Product and Services
2.4.5 CSL Behring Myasthenia Gravis Therapies Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Myasthenia Gravis Therapies Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Myasthenia Gravis Therapies Players Market Share
3.2.2 Top 10 Myasthenia Gravis Therapies Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Myasthenia Gravis Therapies Revenue and Market Share by Regions
4.2 North America Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
4.3 Europe Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
4.5 South America Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
5 North America Myasthenia Gravis Therapies Revenue by Countries
5.1 North America Myasthenia Gravis Therapies Revenue by Countries (2015-2020)
5.2 USA Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
5.3 Canada Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
5.4 Mexico Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
6 Europe Myasthenia Gravis Therapies Revenue by Countries
6.1 Europe Myasthenia Gravis Therapies Revenue by Countries (2015-2020)
6.2 Germany Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
6.3 UK Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
6.4 France Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
6.5 Russia Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
6.6 Italy Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Myasthenia Gravis Therapies Revenue by Countries
7.1 Asia-Pacific Myasthenia Gravis Therapies Revenue by Countries (2015-2020)
7.2 China Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
7.3 Japan Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
7.4 Korea Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
7.5 India Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
8 South America Myasthenia Gravis Therapies Revenue by Countries
8.1 South America Myasthenia Gravis Therapies Revenue by Countries (2015-2020)
8.2 Brazil Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
8.3 Argentina Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Myasthenia Gravis Therapies by Countries
9.1 Middle East & Africa Myasthenia Gravis Therapies Revenue by Countries (2015-2020)
9.2 Saudi Arabia Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
9.3 UAE Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
9.4 Egypt Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
9.5 South Africa Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Myasthenia Gravis Therapies Revenue and Market Share by Type (2015-2020)
10.2 Global Myasthenia Gravis Therapies Market Forecast by Type (2019-2024)
10.3 Ocular Myasthenia Gravis Revenue Growth Rate (2015-2025)
10.4 Congenital Myasthenia Gravis Revenue Growth Rate (2015-2025)
10.5 Generalized Myasthenia Gravis Revenue Growth Rate (2015-2025)
10.6 Transient Myasthenia Gravis Revenue Growth Rate (2015-2025)
10.7 Others Revenue Growth Rate (2015-2025)
11 Global Myasthenia Gravis Therapies Market Segment by Application
11.1 Global Myasthenia Gravis Therapies Revenue Market Share by Application (2015-2020)
11.2 Myasthenia Gravis Therapies Market Forecast by Application (2019-2024)
11.3 Hospitals and Clinics Revenue Growth (2015-2020)
11.4 Diagnostic Centers Revenue Growth (2015-2020)
11.5 Academic and Research Organizations Revenue Growth (2015-2020)
12 Global Myasthenia Gravis Therapies Market Size Forecast (2021-2025)
12.1 Global Myasthenia Gravis Therapies Market Size Forecast (2021-2025)
12.2 Global Myasthenia Gravis Therapies Market Forecast by Regions (2021-2025)
12.3 North America Myasthenia Gravis Therapies Revenue Market Forecast (2021-2025)
12.4 Europe Myasthenia Gravis Therapies Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Myasthenia Gravis Therapies Revenue Market Forecast (2021-2025)
12.6 South America Myasthenia Gravis Therapies Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Myasthenia Gravis Therapies Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables
Table 1. Global Myasthenia Gravis Therapies Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Myasthenia Gravis Therapies by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Myasthenia Gravis Therapies Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Myasthenia Gravis Therapies Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Alexion Pharmaceuticals Corporate Information, Location and Competitors
Table 6. Alexion Pharmaceuticals Myasthenia Gravis Therapies Major Business
Table 7. Alexion Pharmaceuticals Myasthenia Gravis Therapies Total Revenue (USD Million) (2017-2018)
Table 8. Alexion Pharmaceuticals SWOT Analysis
Table 9. Alexion Pharmaceuticals Myasthenia Gravis Therapies Product and Solutions
Table 10. Alexion Pharmaceuticals Myasthenia Gravis Therapies Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Grifols Corporate Information, Location and Competitors
Table 12. Grifols Myasthenia Gravis Therapies Major Business
Table 13. Grifols Myasthenia Gravis Therapies Total Revenue (USD Million) (2018-2019)
Table 14. Grifols SWOT Analysis
Table 15. Grifols Myasthenia Gravis Therapies Product and Solutions
Table 16. Grifols Myasthenia Gravis Therapies Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Novartis Corporate Information, Location and Competitors
Table 18. Novartis Myasthenia Gravis Therapies Major Business
Table 19. Novartis Myasthenia Gravis Therapies Total Revenue (USD Million) (2017-2018)
Table 20. Novartis SWOT Analysis
Table 21. Novartis Myasthenia Gravis Therapies Product and Solutions
Table 22. Novartis Myasthenia Gravis Therapies Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. CSL Behring Corporate Information, Location and Competitors
Table 24. CSL Behring Myasthenia Gravis Therapies Major Business
Table 25. CSL Behring Myasthenia Gravis Therapies Total Revenue (USD Million) (2017-2018)
Table 26. CSL Behring SWOT Analysis
Table 27. CSL Behring Myasthenia Gravis Therapies Product and Solutions
Table 28. CSL Behring Myasthenia Gravis Therapies Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Global Myasthenia Gravis Therapies Revenue (Million USD) by Players (2015-2020)
Table 30. Global Myasthenia Gravis Therapies Revenue Share by Players (2015-2020)
Table 31. Global Myasthenia Gravis Therapies Revenue (Million USD) by Regions (2015-2020)
Table 32. Global Myasthenia Gravis Therapies Revenue Market Share by Regions (2015-2020)
Table 33. North America Myasthenia Gravis Therapies Revenue by Countries (2015-2020)
Table 34. North America Myasthenia Gravis Therapies Revenue Market Share by Countries (2015-2020)
Table 35. Europe Myasthenia Gravis Therapies Revenue (Million USD) by Countries (2015-2020)
Table 36. Asia-Pacific Myasthenia Gravis Therapies Revenue (Million USD) by Countries (2015-2020)
Table 37. South America Myasthenia Gravis Therapies Revenue by Countries (2015-2020)
Table 38. South America Myasthenia Gravis Therapies Revenue Market Share by Countries (2015-2020)
Table 39. Middle East and Africa Myasthenia Gravis Therapies Revenue (Million USD) by Countries (2015-2020)
Table 40. Middle East and Africa Myasthenia Gravis Therapies Revenue Market Share by Countries (2015-2020)
Table 41. Global Myasthenia Gravis Therapies Revenue (Million USD) by Type (2015-2020)
Table 42. Global Myasthenia Gravis Therapies Revenue Share by Type (2015-2020)
Table 43. Global Myasthenia Gravis Therapies Revenue Forecast by Type (2021-2025)
Table 44. Global Myasthenia Gravis Therapies Revenue by Application (2015-2020)
Table 45. Global Myasthenia Gravis Therapies Revenue Share by Application (2015-2020)
Table 46. Global Myasthenia Gravis Therapies Revenue Forecast by Application (2021-2025)
Table 47. Global Myasthenia Gravis Therapies Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Myasthenia Gravis Therapies Picture
Figure 2. Global Myasthenia Gravis Therapies Revenue Market Share by Type in 2019
Figure 3. Ocular Myasthenia Gravis Picture
Figure 4. Congenital Myasthenia Gravis Picture
Figure 5. Generalized Myasthenia Gravis Picture
Figure 6. Transient Myasthenia Gravis Picture
Figure 7. Others Picture
Figure 8. Myasthenia Gravis Therapies Revenue Market Share by Application in 2019
Figure 9. Hospitals and Clinics Picture
Figure 10. Diagnostic Centers Picture
Figure 11. Academic and Research Organizations Picture
Figure 12. Global Myasthenia Gravis Therapies Revenue (USD Million) and Growth Rate (2015-2025)
Figure 13. North America Myasthenia Gravis Therapies Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Europe Myasthenia Gravis Therapies Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Asia-Pacific Myasthenia Gravis Therapies Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. South America Myasthenia Gravis Therapies Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Middle East and Africa Myasthenia Gravis Therapies Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Global Myasthenia Gravis Therapies Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Global Myasthenia Gravis Therapies Revenue Share by Players in 2019
Figure 20. Global Top 5 Players Myasthenia Gravis Therapies Revenue Market Share in 2019
Figure 21. Global Top 10 Players Myasthenia Gravis Therapies Revenue Market Share in 2019
Figure 22. Key Players Market Share Trend
Figure 23. Global Myasthenia Gravis Therapies Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 24. Global Myasthenia Gravis Therapies Revenue Market Share by Regions (2015-2020)
Figure 25. Global Myasthenia Gravis Therapies Revenue Market Share by Regions in 2018
Figure 26. North America Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
Figure 27. Europe Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
Figure 28. Asia-Pacific Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
Figure 29. South America Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
Figure 30. Middle East and Africa Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
Figure 31. North America Myasthenia Gravis Therapies Revenue Market Share by Countries (2015-2020)
Figure 32. North America Myasthenia Gravis Therapies Revenue Market Share by Countries in 2019
Figure 33. USA Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
Figure 34. Canada Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
Figure 35. Mexico Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
Figure 36. Europe Myasthenia Gravis Therapies Revenue Market Share by Countries (2015-2020)
Figure 37. Europe Myasthenia Gravis Therapies Revenue Market Share by Countries in 2019
Figure 38. Germany Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
Figure 39. UK Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
Figure 40. France Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
Figure 41. Russia Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
Figure 42. Italy Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
Figure 43. Asia-Pacific Myasthenia Gravis Therapies Revenue Market Share by Countries (2015-2020)
Figure 44. Asia-Pacific Myasthenia Gravis Therapies Revenue Market Share by Countries in 2019
Figure 45. China Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
Figure 46. Japan Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
Figure 47. Korea Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
Figure 48. India Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
Figure 49. Southeast Asia Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
Figure 50. South America Myasthenia Gravis Therapies Revenue Market Share by Countries (2015-2020)
Figure 51. South America Myasthenia Gravis Therapies Revenue Market Share by Countries in 2019
Figure 52. Brazil Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
Figure 53. Argentina Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
Figure 54. Middle East and Africa Myasthenia Gravis Therapies Revenue Market Share by Countries (2015-2020)
Figure 55. Middle East and Africa Myasthenia Gravis Therapies Revenue Market Share by Countries in 2019
Figure 56. Saudi Arabia Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
Figure 57. UAE Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
Figure 58. Egypt Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
Figure 59. South Africa Myasthenia Gravis Therapies Revenue and Growth Rate (2015-2020)
Figure 60. Global Myasthenia Gravis Therapies Revenue Share by Type (2015-2020)
Figure 61. Global Myasthenia Gravis Therapies Revenue Share by Type in 2019
Figure 62. Global Myasthenia Gravis Therapies Market Share Forecast by Type (2021-2025)
Figure 63. Global Ocular Myasthenia Gravis Revenue Growth Rate (2015-2020)
Figure 64. Global Congenital Myasthenia Gravis Revenue Growth Rate (2015-2020)
Figure 65. Global Generalized Myasthenia Gravis Revenue Growth Rate (2015-2020)
Figure 66. Global Transient Myasthenia Gravis Revenue Growth Rate (2015-2020)
Figure 67. Global Others Revenue Growth Rate (2015-2020)
Figure 68. Global Myasthenia Gravis Therapies Revenue Share by Application (2015-2020)
Figure 69. Global Myasthenia Gravis Therapies Revenue Share by Application in 2019
Figure 70. Global Myasthenia Gravis Therapies Market Share Forecast by Application (2021-2025)
Figure 71. Global Hospitals and Clinics Revenue Growth Rate (2015-2020)
Figure 72. Global Diagnostic Centers Revenue Growth Rate (2015-2020)
Figure 73. Global Academic and Research Organizations Revenue Growth Rate (2015-2020)
Figure 74. Global Myasthenia Gravis Therapies Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 75. Global Myasthenia Gravis Therapies Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 76. Global Myasthenia Gravis Therapies Revenue Market Share Forecast by Regions (2021-2025)
Figure 77. North America Myasthenia Gravis Therapies Revenue Market Forecast (2021-2025)
Figure 78. Europe Myasthenia Gravis Therapies Revenue Market Forecast (2021-2025)
Figure 79. Asia-Pacific Myasthenia Gravis Therapies Revenue Market Forecast (2021-2025)
Figure 80. South America Myasthenia Gravis Therapies Revenue Market Forecast (2021-2025)
Figure 81. Middle East and Africa Myasthenia Gravis Therapies Revenue Market Forecast (2021-2025)
Figure 82. Sales Channel: Direct Channel vs Indirect Channel

---